Zobrazit v EDS

Is the C reactive protein/albumin ratio a good tool for retinal vein occlusion?

Uloženo v:
Podrobná bibliografie
Název: Is the C reactive protein/albumin ratio a good tool for retinal vein occlusion?
Autoři: Vural E; Wold Eye Hospital, İstanbul, Turkey. vural_esra@yahoo.com., Hazar L; Department of Ophthalmology, Dicle University School of Medicine, Diyarbakır, Turkey.
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2025 Nov 25; Vol. 25 (1), pp. 664. Date of Electronic Publication: 2025 Nov 25.
Způsob vydávání: Journal Article
Jazyk: English
Informace o časopise: Publisher: BioMed Central Country of Publication: England NLM ID: 100967802 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2415 (Electronic) Linking ISSN: 14712415 NLM ISO Abbreviation: BMC Ophthalmol Subsets: MEDLINE
Imprint Name(s): Original Publication: London : BioMed Central, [2001-
Výrazy ze slovníku MeSH: Retinal Vein Occlusion*/blood , Retinal Vein Occlusion*/diagnosis , C-Reactive Protein*/metabolism , Serum Albumin*/metabolism, Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Biomarkers/blood ; Aged ; ROC Curve ; Lymphocytes ; Neutrophils ; Adult
Abstrakt: Competing Interests: Declarations. Ethical approval and informed consent statements: The study was approved by the local ethics committee from Kayseri City Hospital. Informed consent was obtained from all of the participants in the study. Competing interests: The authors declare no competing interests.
Background: Local and systemic inflammation may play a role in the development of retinal vein occlusion (RVO). The C-reactive protein (CRP)/albumin ratio is a useful prognostic indicator in various systemic inflammatory conditions. The aim of this study was to evaluate the levels of systemic blood markers of inflammation, including CRP/albumin ratio, in RVO.
Methods: The files of patients diagnosed with RVO were retrospectively reviewed. Thirty-four patients with RVO and 34 age- and sex-matched controls were included in the study. The control group consisted of age- and sex-matched subjects who visited the ophthalmology outpatient clinic for a routine eye examination. C-reactive protein (CRP) levels, albumin levels, and neutrophil, lymphocyte, monocyte, and platelet counts were recorded. The CRP/albumin ratio, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated.
Results: The mean age of group 1 was 58.73 ± 12.61, and group 2 was 59.17 ± 9.93 (p = 0.873). The female/male ratio was 18/16 in group 1 and 12/22 in group 2 (p = 0.111). CRP/Albumin ratio was 0.57 ± 0.40 in group 1, 0.36 ± 0.33 in group 2 (p = 0.020). The CRP/albumin ratio was significantly higher in the patients with RVO as compared with that in the controls. A significant correlation was found between the CRP/albumin ratio and visual acuity (LogMAR) (r = 0.356, p = 0.003). According to a receiver operator characteristic (ROC) curve analysis, the cut-off value of the CRP/albumin ratio for RVO was 0.42, with sensitivity of 79% and specificity of 55%. A significant correlation was found between the CRP/albumin ratio and visual acuity. There was no significant difference between the two groups in terms of the NLR, PLR, and SII.
Conclusion: The CRP/albumin ratio is a better inflammation marker than the NLR, PLR, and SII in RVO.
(© 2025. The Author(s).)
References: Prev Med. 2005 Aug;41(2):651-6. (PMID: 15917065)
Ophthalmol Ther. 2022 Jun;11(3):1241-1249. (PMID: 35503164)
Clin Neurol Neurosurg. 2020 Aug;195:106051. (PMID: 32650209)
Invest Ophthalmol Vis Sci. 2008 May;49(5):2053-60. (PMID: 18436840)
J Curr Ophthalmol. 2023 Dec 21;35(2):177-181. (PMID: 38250487)
Clin Chim Acta. 2020 Nov;510:26-27. (PMID: 32649954)
Curr Eye Res. 2008 Feb;33(2):111-31. (PMID: 18293182)
PLoS One. 2015 Dec 04;10(12):e0144406. (PMID: 26636823)
Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2778-82. (PMID: 25339469)
Ophthalmology. 2010 Feb;117(2):313-9.e1. (PMID: 20022117)
Kidney Int. 1997 Sep;52(3):761-70. (PMID: 9291198)
Curr Opin Hematol. 2006 Jan;13(1):34-9. (PMID: 16319685)
Saudi J Ophthalmol. 2016 Apr-Jun;30(2):105-8. (PMID: 27330385)
Biomolecules. 2018 Aug 23;8(3):. (PMID: 30142970)
Eur J Intern Med. 2017 Oct;44:44-48. (PMID: 28684050)
Ocul Immunol Inflamm. 2023 Apr;31(3):491-495. (PMID: 35201964)
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1025-32. (PMID: 19060280)
JAMA. 1998 May 13;279(18):1477-82. (PMID: 9600484)
Mol Vis. 2019 Nov 15;25:756-765. (PMID: 31814701)
Postepy Kardiol Interwencyjnej. 2017;13(1):32-38. (PMID: 28344615)
Can J Ophthalmol. 2007 Feb;42(1):131-3. (PMID: 17361257)
Obes Surg. 2024 Sep;34(9):3372-3381. (PMID: 39044117)
Ophthalmic Epidemiol. 2021 Feb;28(1):39-47. (PMID: 32648802)
Ophthalmology. 2005 Apr;112(4):540-7. (PMID: 15808241)
Blood Coagul Fibrinolysis. 2008 Jun;19(4):259-62. (PMID: 18469545)
Kaohsiung J Med Sci. 2015 Dec;31(12):626-31. (PMID: 26709224)
Am J Epidemiol. 2006 Nov 15;164(10):969-77. (PMID: 16980573)
Clin Appl Thromb Hemost. 2015 Mar;21(2):181-5. (PMID: 23814171)
Platelets. 1996;7(3):125-37. (PMID: 21043591)
Clin Chem. 2009 Feb;55(2):229-38. (PMID: 19095731)
J Am Coll Cardiol. 2007 Sep 18;50(12):1115-22. (PMID: 17868801)
J Ophthalmol. 2019 Oct 31;2019:6043612. (PMID: 31885890)
Immunol Res. 2004;30(3):261-77. (PMID: 15531769)
Sci Rep. 2021 Mar 8;11(1):5446. (PMID: 33686103)
Contributed Indexing: Keywords: C-reactive protein; Lymphocyte; Neutrophil; Retinal vein occlusion; Systemic inflammation
Substance Nomenclature: 9007-41-4 (C-Reactive Protein)
0 (Biomarkers)
0 (Serum Albumin)
Entry Date(s): Date Created: 20251126 Date Completed: 20251126 Latest Revision: 20251128
Update Code: 20251128
PubMed Central ID: PMC12648851
DOI: 10.1186/s12886-025-04483-0
PMID: 41291569
Databáze: MEDLINE
Popis
Abstrakt:Competing Interests: Declarations. Ethical approval and informed consent statements: The study was approved by the local ethics committee from Kayseri City Hospital. Informed consent was obtained from all of the participants in the study. Competing interests: The authors declare no competing interests.<br />Background: Local and systemic inflammation may play a role in the development of retinal vein occlusion (RVO). The C-reactive protein (CRP)/albumin ratio is a useful prognostic indicator in various systemic inflammatory conditions. The aim of this study was to evaluate the levels of systemic blood markers of inflammation, including CRP/albumin ratio, in RVO.<br />Methods: The files of patients diagnosed with RVO were retrospectively reviewed. Thirty-four patients with RVO and 34 age- and sex-matched controls were included in the study. The control group consisted of age- and sex-matched subjects who visited the ophthalmology outpatient clinic for a routine eye examination. C-reactive protein (CRP) levels, albumin levels, and neutrophil, lymphocyte, monocyte, and platelet counts were recorded. The CRP/albumin ratio, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated.<br />Results: The mean age of group 1 was 58.73 ± 12.61, and group 2 was 59.17 ± 9.93 (p = 0.873). The female/male ratio was 18/16 in group 1 and 12/22 in group 2 (p = 0.111). CRP/Albumin ratio was 0.57 ± 0.40 in group 1, 0.36 ± 0.33 in group 2 (p = 0.020). The CRP/albumin ratio was significantly higher in the patients with RVO as compared with that in the controls. A significant correlation was found between the CRP/albumin ratio and visual acuity (LogMAR) (r = 0.356, p = 0.003). According to a receiver operator characteristic (ROC) curve analysis, the cut-off value of the CRP/albumin ratio for RVO was 0.42, with sensitivity of 79% and specificity of 55%. A significant correlation was found between the CRP/albumin ratio and visual acuity. There was no significant difference between the two groups in terms of the NLR, PLR, and SII.<br />Conclusion: The CRP/albumin ratio is a better inflammation marker than the NLR, PLR, and SII in RVO.<br /> (© 2025. The Author(s).)
ISSN:1471-2415
DOI:10.1186/s12886-025-04483-0